Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Publication year range
1.
J Neurooncol ; 2024 Jul 23.
Article in English | MEDLINE | ID: mdl-39044115

ABSTRACT

PURPOSE: The objective of this prospective, single-centre case series was to investigate feasibility, clinical outcomes, and neural correlates of non-invasive Neuromodulation-Induced Cortical Prehabilitation (NICP) before brain tumor surgery. Previous studies have shown that gross total resection is paramount to increase life expectancy but is counterbalanced by the need of preserving critical functional areas. NICP aims at expanding functional margins for extensive tumor resection without functional sequelae. Invasive NICP (intracranial neuromodulation) was effective but characterized by elevated costs and high rate of adverse events. Non-invasive NICP (transcranial neuromodulation) may represent a more feasible alternative. Nonetheless, up to this point, non-invasive NICP has been examined in only two case reports, yielding inconclusive findings. METHODS: Treatment sessions consisted of non-invasive neuromodulation, to transiently deactivate critical areas adjacent to the lesion, coupled with intensive functional training, to activate alternative nodes within the same functional network. Patients were evaluated pre-NICP, post-NICP, and at follow-up post-surgery. RESULTS: Ten patients performed the intervention. Feasibility criteria were met (retention, adherence, safety, and patient's satisfaction). Clinical outcomes showed overall stability and improvements in motor and executive function from pre- to post-NICP, and at follow-up. Relevant plasticity changes (increase in the distance between tumor and critical area) were observed when the neuromodulation target was guided by functional neuroimaging data. CONCLUSION: This is the first case series demonstrating feasibility of non-invasive NICP. Neural correlates indicate that neuroimaging-guided target selection may represent a valid strategy to leverage neuroplastic changes before neurosurgery. Further investigations are needed to confirm such preliminary findings.

2.
Neurocir. - Soc. Luso-Esp. Neurocir ; 24(5): 204-209, sept.-oct. 2013. tab
Article in Spanish | IBECS | ID: ibc-127175

ABSTRACT

Objetivo Presentar la experiencia en el tratamiento de la epilepsia resistente a los fármacos mediante estimulación del nervio vago (ENV) en nuestro centro, valorando el impacto de este tratamiento sobre el control de la enfermedad, así como sobre aspectos relacionados con la calidad de vida de los pacientes y de sus cuidadores principales. Material y métodos Se realizó un análisis retrospectivo de los pacientes implantados desde enero de 2004 hasta diciembre de 2012. Se evaluaron los resultados de encuestas y test completados por los pacientes y sus cuidadores principales. Resultados Se incluyeron 15 pacientes con un seguimiento medio tras la cirugía de 4,41 (0,5-8) años. La edad media en el momento de la cirugía fue de 25 (10-50) años. Más del 66% de los pacientes experimentaron una disminución en la intensidad de las crisis > 25%. El 47% presentó una reducción > 50% en la frecuencia de las mismas. Como efectos adversos indeseables un paciente presentó disfonía persistente, otro tos y molestias cervicales autolimitados, y otro molestias cervicales. En 2 pacientes fue necesaria la explantación por cefalea refractaria al tratamiento médico. No hubo complicaciones derivadas del acto (AU)


OBJECTIVE: To present our experience in treating drug-resistant epilepsy with vagal nerve stimulation in our centre, evaluating its impact on disease control and on different aspects related to the patients and main caretakers' quality of life. MATERIALS AND METHODS: This was a retrospective analysis of patients operated from January 2004 until December 2012. Interviews and tests completed by outpatients and principle caretakers were evaluated. RESULTS: Fifteen patients were included, with a mean postoperative follow-up of 4.41 (0.5-8) years. Mean age at implantation was 25 (10-50) years. Over 66% of the patients perceived a reduction greater than 25% of their crisis intensity. Forty-seven percent of the patients experienced a decrease greater than 50% in the number of crises. As undesired adverse events, one patient presented persistent dysphonia, another self-limited cough and cervical discomfort and another, persistent cervical discomfort. The device had to be removed in 2 patients due to refractory headaches. There were no complications derived from the surgical procedure. CONCLUSIONS: Vagal nerve stimulation is an effective treatment for reducing crisis frequency and intensity. The patients as well as their caretakers experience a subjective improvement in their quality of life. Despite its economic cost, it seems to reduce their care needs to a certain degree and its use may therefore be justified (AU)


Subject(s)
Humans , Epilepsy/therapy , Transcutaneous Electric Nerve Stimulation/methods , Vagus Nerve Stimulation/methods , Receptors, Neurotransmitter , Drug Resistance , Anticonvulsants/therapeutic use
3.
Neurocirugia (Astur) ; 24(5): 204-9, 2013.
Article in Spanish | MEDLINE | ID: mdl-23850134

ABSTRACT

OBJECTIVE: To present our experience in treating drug-resistant epilepsy with vagal nerve stimulation in our centre, evaluating its impact on disease control and on different aspects related to the patients and main caretakers' quality of life. MATERIALS AND METHODS: This was a retrospective analysis of patients operated from January 2004 until December 2012. Interviews and tests completed by outpatients and principle caretakers were evaluated. RESULTS: Fifteen patients were included, with a mean postoperative follow-up of 4.41 (0.5-8) years. Mean age at implantation was 25 (10-50) years. Over 66% of the patients perceived a reduction greater than 25% of their crisis intensity. Forty-seven percent of the patients experienced a decrease greater than 50% in the number of crises. As undesired adverse events, one patient presented persistent dysphonia, another self-limited cough and cervical discomfort and another, persistent cervical discomfort. The device had to be removed in 2 patients due to refractory headaches. There were no complications derived from the surgical procedure. CONCLUSIONS: Vagal nerve stimulation is an effective treatment for reducing crisis frequency and intensity. The patients as well as their caretakers experience a subjective improvement in their quality of life. Despite its economic cost, it seems to reduce their care needs to a certain degree and its use may therefore be justified.


Subject(s)
Epilepsy/therapy , Vagus Nerve Stimulation , Adult , Drug Resistance , Epilepsy/drug therapy , Hospitals, University , Humans , Retrospective Studies , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...